Process Gets Overlooked in the Obsession With Outcomes in Oncology

Maurie Markman, MD
Published: Thursday, Feb 14, 2019
Maurie Markman, MD

Maurie Markman, MD
It is not difficult to identify multiple examples of the success of precision cancer medicine. One can begin with the decades-old observation that patients with breast cancer whose malignancies overexpress the estrogen receptor are appropriate candidates for antiestrogen therapy, followed by the knowledge that a mutation in the catalytic domain of EGFR is a biomarker for patients with lung cancer who should receive an EGFR inhibitor. Further, BRAF mutations are key to determining who among those with metastatic melanoma may benefit from an inhibitor of this target.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication